Oncology News | pharmaphorum

News

Merck KGaA offloads failed MEK programme to startup Day One

US biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s pipeline for years, in the hope of giving it a new lease of life.

News

FDA to quickly review Incyte's Jakafi in chronic GVHD

The FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease (GVHD), which cannot be treated with steroids.

News

Sanofi's immunotherapy Libtayo gets FDA approval in first li...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients.

News

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Limited access to cancer biomarker testing in Europe, report...

There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report.

News

MHRA approves Seagen’s oral HER2 drug Tukysa

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission.

News

Nektar lifted by Merck alliance for bempeg, new trial fundin...

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, but that hasn’

Merck KGaA offloads failed MEK programme to startup Day One

FDA to quickly review Incyte's Jakafi in chronic GVHD

Sanofi's immunotherapy Libtayo gets FDA approval in first li...

Limited access to cancer biomarker testing in Europe, report...

MHRA approves Seagen’s oral HER2 drug Tukysa

Nektar lifted by Merck alliance for bempeg, new trial fundin...

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks